miR-34a is downregulated in cis-diamminedichloroplatinum treated sinonasal squamous cell carcinoma patients with poor prognosis

Cancer Science

Volumn 103, Issue 9, 2012, Pages 1737-1743

  Ogawa, Takenori ^a   Saiki, Yuriko ^a   Shiga, Kiyoto ^a   Chen, Na ^a   Fukushige, Shinichi ^a   Sunamura, Makoto ^a,b   Nagase, Hiroki ^c   Hashimoto, Sho ^d   Matsuura, Kazuto ^e   Saijo, Shigeru ^e   Kobayashi, Toshimitsu ^a   Horii, Akira ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKYO MEDICAL UNIVERSITY HACHIOJI MEDICAL CENTER   (Japan)

^c NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d SENDAI CITY MEDICAL CENTER   (Japan)

^e Miyagi Cancer Center   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; MICRORNA 34A;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER CONTROL; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; MICROARRAY ANALYSIS; NOSE CARCINOMA; PARANASAL SINUS CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; MIDDLE AGED; PARANASAL SINUS NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84865733548     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02338.x     Document Type: Article

References (33)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 ver. 1.2, Cancer Incidence and Mortality Worldwide. IARC CancerBase, No10. Lyon: International Agency for Research on Cancer, 2010. Available from URL: http://globocan.iarc.fr.
2. Ogawa T, Furukawa T, Shiga K et al. A cDNA microarray analysis identifies 52 genes associated with CDDP susceptibility in head and neck squamous cell carcinoma cell lines. Eur Arch Otorhinolaryngol 2010; 267: 123-9.
3. Ogawa T, Ogawa K, Shiga K et al. Upregulation of IGF2 is associated with an acquired resistance for cis-diamminedichloroplatinum in human head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol 2010; 267: 1599-606.
4. Forastiere AA, Goepfert H, Maor M et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003; 349: 2091-8.
5. Adelstein DJ, Li Y, Adams GL et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003; 21: 92-8.
6. Bernier J, Domenge C, Ozsahin M et al. European Organization for Research and Treatment of Cancer Trial 22931 Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350: 1945-52.
7. Rosenberg B, Vancamp L, Trosko JE, Mansour VH. Platinum compounds: a new class of potent antitumour agents. Nature 1969; 222: 385-6.
8. Saiki Y, Ogawa T, Shiga K, Sunamura M, Kobayashi T, Horii A. A human head and neck squamous cell carcinoma cell line with acquired cis-diamminedichloroplatinum-resistance shows remarkable upregulation of BRCA1 and hypersensitivity to taxane. Int J Otolaryngol 2011; 2011: 521852.
9. Andrews PA, Howell SB. Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells 1990; 2: 35-43.
10. Hoskins LK, Whelan RD, Shellard SA, Bedford P, Hill BT. An evaluation of the role of glutathione and its associated enzymes in the expression of differential sensitivities to antitumor agents shown by a range of human tumour cell lines. Biochem Pharmacol 1990; 40: 1833-42.
11. Hospers GA, Meijer C, de Leij L, Uges DR, Mulder NH, de Vries EG. A study of human small-cell lung carcinoma (hSCLC) cell lines with different sensitivities to detect relevant mechanisms of cisplatin (CDDP) resistance. Int J Cancer 1990; 46: 138-44.
12. Meijer C, Mulder NH, Timmer-Bosscha H, Sluiter WJ, Meersma GJ, de Vries EG. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. Cancer Res 1992; 52: 6885-9.
13. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75: 843-54.
14. Scaria V, Hariharan M, Pillai B, Maiti S, Brahmachari SK. Host-virus genome interractions: macro roles for microRNAs. Cell Microbiol 2007; 9: 2784-94.
15. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-66.
16. Esquela-Kerscher A, Slack EJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006; 6: 259-69.
17. Chang SS, Jiang WW, Smith I et al. MicroRNA alterations in head and neck squamous cell carcinoma. Int J Cancer 2008; 123: 2791-7.
18. Galluzzi L, Morselli E, Vitale I et al. miR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res 2010; 70: 1793-803.
19. Zhu W, Shan X, Wang T, Shu Y, Liu P. miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010; 127: 2520-9.
20. Hamano R, Miyata H, Yamasaki M et al. Overexpression of miR-200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway. Clin Cancer Res 2011; 17: 3029-38.
21. Yang H, Kong W, He L, Zhao JJ et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 2008; 68: 425-33.
22. Pogribny IP, Filkowski JN, Tryndyak VP, Golubov A, Shpyleva SI, Kovalchuk O. Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int J Cancer 2010; 127: 1785-94.
23. Shiga K, Yokoyama J, Hashimoto S et al. Combined therapy after superselective arterial cisplatin infusion to treat maxillary squamous cell carcinoma. Otolaryngol Head Neck Surg 2007; 136: 1003-9.
24. International Union Against Cancer. TNM Classification of Malignant Tumours, 6th edn. New York: Wiley-Liss, 2002; 43-5.
25. Kondo E, Horii A, Fukushige S. The human PMS2L proteins do not interact with hMLH1, a major DNA mismatch repair protein. J Biochem 1999; 125: 818-25.
26. Ogawa T, Shiga K, Hashimoto S, Kobayashi T, Horii A, Furukawa T. APAF-1-ALT, a novel alternative splicing form of APAF-1, potentially causes impeded ability of undergoing DNA damage-induced apoptosis in the LNCaP human prostate cancer cell line. Biochem Biophys Res Commun 2003; 306: 537-43.
27. Ma L, Ronai A, Riede UN, Köhler G. Clinical implication of screening p53 gene mutations in head and neck squamous cell carcinomas. J Cancer Res Clin Oncol 1998; 124: 389-96.
28. Akao Y, Noguchi S, Iio A, Kojima K, Takagi T, Naoe T. Dysregulation of microRNA-34a expression causes drug-resistance to 5-FU in human colon cancer DLD-1 cells. Cancer Lett 2011; 300: 197-204.
29. Weeraratne SD, Amani V, Neiss A et al. miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma. Neuro Oncol 2011; 13: 165-75.
30. Ji Q, Hao X, Zhang M et al. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One 2009; 4: e6816.
31. Gallardo E, Navarro A, Viñolas N et al. miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis 2009; 30: 1903-9.
32. Kumamoto K, Spillare EA, Fujita K et al. Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence. Cancer Res 2008; 68: 3193-203.
33. Chang T-C, Wentzel EA, Kent OA et al. Transactivation of miR-34a by p53 broadly influences gene expression and promote apoptosis. Mol Cell 2007; 26: 745-52.